Opthea is developing novel biologic inhibitors of angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth) and vascular leakage for the treatment of ophthalmic diseases.


Opthea's lead compound, OPT-302, is a soluble receptor that specifically and potently blocks the activity of two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, that are involved in the progression of both retinal and corneal diseases.  


Opthea is currently developing OPT-302 for the treatment of wet age-related macular degeneration (wet AMD).


Opthea Pty Ltd is a private, 100% owned subsidiary of Circadian Technologies Limited based in Melbourne, Australia.  Enquiries can be directed to: info@opthea.com


Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) reports that Dr Kameran Lashkari of Sc Read More...

Opthea's April 2015 Newsletter includes: Letter from the CEO, a summary of our preclinical da Read More...

Circadian Technologies' (CIR: $0.18) CEO Megan Baldwin gave an update to investors recently, Read More...


To receive notifications about Opthea, subscribe to our distribution list.